Kyleena

Levonorgestrel, the active ingredient in Kyleena, is a progestin presented as a 19.5 mg intrauterine system (IUS) for intrauterine use. Delivered directly to the uterine cavity, it releases hormone continuously to provide long‑acting reversible contraception for women of reproductive age.

GNH USA supplies Kyleena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality compliance with EU standards and provides global logistics support.

Kyleena, a levonorgestrel‑based intrauterine system, is indicated for hormonal contraception.

- Contraception: Prevents pregnancy for up to five years with a single insertion. - Hormonal birth control: Provides continuous progestin release to suppress ovulation in many cycles. - Menstrual management: May reduce menstrual blood loss and lessen dysmenorrhea in some users.

Side effects associated with Kyleena vary in frequency and severity.

Common Side Effects: - Irregular bleeding or spotting - Amenorrhea (absence of periods) - Pelvic or cramping pain after insertion - Headache - Breast tenderness

Serious or Rare Side Effects: - Uterine perforation - Expulsion of the device - Pelvic infection (e.g., PID) - Ectopic pregnancy if contraception fails

Key precautions should be observed before and after Kyleena insertion.

- Pregnancy testing: Confirm the patient is not pregnant prior to insertion. - Uterine abnormalities: Contraindicated in known uterine malformations or fibroids that distort the cavity. - Active infection: Do not insert in the presence of pelvic inflammatory disease or untreated sexually transmitted infection. - Breastfeeding: Use with caution during the early postpartum period, especially within six weeks after delivery. - Smoking: Advise women over 35 who smoke to consider alternative contraception. - Store at ambient temperature: Keep the device in its original packaging, protect from moisture and direct sunlight.

Levonorgestrel efficacy can be altered by concomitant medications.

Major Interactions (Avoid): - Enzyme inducers (e.g., rifampin, carbamazepine) may reduce levonorgestrel levels and decrease contraceptive effectiveness. - Antiepileptic drugs (e.g., phenytoin, phenobarbital) can similarly lower hormone concentrations.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole) may increase levonorgestrel exposure, requiring monitoring for hormonal side effects. - Certain antibiotics (e.g., tetracycline, metronidazole) have limited evidence of interaction but should be observed. - Herbal supplements such as St. John’s wort may induce metabolism and reduce efficacy.